- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07450547
Fase 2-studie for å vurdere sikkerheten og effekten av ANG003
En fase 2, multicentrisk, randomisert, aktivkontrollert studie for å vurdere sikkerheten og effekten av ANG003 ved to forskjellige dosenivåer hos pasienter med eksokrin pankreasinsuffisiens på grunn av cystisk fibrose
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Evan Bailey, MD
- Telefonnummer: 617-466-3111
- E-post: medical@anagramtx.com
Studiesteder
-
-
California
-
Long Beach, California, Forente stater, 90806
- Rekruttering
- Long Beach Memorial Medical Center
-
Ta kontakt med:
- Angelica Rodriguez
- Telefonnummer: 562-706-1245
- E-post: ARodriguez9@memorialcare.org
-
Los Angeles, California, Forente stater, 90033
- Rekruttering
- Center for Cystic Fibrosis at Keck Medical Center of USC
-
Ta kontakt med:
- Lynn Fukushima
- Telefonnummer: 323-442-8522
- E-post: lynn.fukushima@med.usc.edu
-
-
Colorado
-
Denver, Colorado, Forente stater, 80206
- Rekruttering
- National Jewish Health
-
Ta kontakt med:
- Alix Wilson
- Telefonnummer: 303-270-2517
- E-post: wilsona@njhealth.org
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- Har ikke rekruttert ennå
- University of Florida
-
Ta kontakt med:
- Alexa Smith
- Telefonnummer: 352-273-8380
- E-post: alexa.howell@ufl.edu
-
Orlando, Florida, Forente stater, 32803
- Har ikke rekruttert ennå
- Central Florida Pulmonary Group
-
Ta kontakt med:
- Desiree Serr
- Telefonnummer: 407-303-7192
- E-post: desiree.serr1@adventhealth.com
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30324
- Rekruttering
- Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
-
Ta kontakt med:
- Eric Hunter
- Telefonnummer: 678-977-5212
- E-post: eahunte@emory.edu
-
-
Illinois
-
Glenview, Illinois, Forente stater, 60025
- Rekruttering
- The Cystic Fibrosis Institute
-
Ta kontakt med:
- Steven R Boas, MD
- Telefonnummer: 847-998-3434
- E-post: sboas@wecare4lungs.com
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Har ikke rekruttert ennå
- University of Iowa
-
Ta kontakt med:
- Mary Teresi
- Telefonnummer: 319-384-7546
- E-post: mary-teresi@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- University of Kansas Medical Center
-
Ta kontakt med:
- Lawrence Scott
- Telefonnummer: 913-588-4020
- E-post: lscott2@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40506
- Rekruttering
- University of Kentucky
-
Ta kontakt med:
- Chase Whitaker
- Telefonnummer: 859-218-4810
- E-post: chase.whitaker@uky.edu
-
-
Maine
-
Portland, Maine, Forente stater, 04102
- Har ikke rekruttert ennå
- MaineHealth Pediatric Specialty Care
-
Ta kontakt med:
- Rebecca Edwards
- Telefonnummer: 207-662-6712
- E-post: rebecca.edwards@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Ta kontakt med:
- Margot Hardcastle
- Telefonnummer: 617-726-3719
- E-post: mhardcastle@mgh.harvard.edu
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Boston Children's Hospita
-
Ta kontakt med:
- Robert Fowler
- Telefonnummer: 617-355-1834
- E-post: Robert.fowler@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan, Michigan Medicine
-
Ta kontakt med:
- Dawn Kruse
- Telefonnummer: 734-615-3266
- E-post: dmkruse@med.umich.edu
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Wayne State University Harper University Hospital
-
Ta kontakt med:
- Debra Driscoll
- Telefonnummer: 313-745-2221
- E-post: ddriscol@med.wayne.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- Rekruttering
- University of Minnesota
-
Ta kontakt med:
- Brooke Noren, RN, BSN, CCRC
- Telefonnummer: 612-625-7995
- E-post: boer0039@umn.edu
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08903
- Rekruttering
- Rutgers - Robert Wood Johnson Medical School
-
Ta kontakt med:
- Sheila Redding
- Telefonnummer: 732-235-7840
- E-post: sr1238@rwjms.rutgers.edu
-
-
New York
-
Valhalla, New York, Forente stater, 10595
- Har ikke rekruttert ennå
- New York Medical College at Westchester Medical Center
-
Ta kontakt med:
- Zachary Messer
- Telefonnummer: 914-594-2352
- E-post: Zachary_Messer@nymc.edu
-
-
Ohio
-
Akron, Ohio, Forente stater, 44308
- Rekruttering
- Children's Hospital Medical Center of Akron
-
Ta kontakt med:
- Michelle Parrish
- Telefonnummer: 330-543-3089
- E-post: MParrish@akronchildrens.org
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
-
Ta kontakt med:
- Primary RC & Participant Contact General Contact
- Telefonnummer: 216-844-3911
- E-post: RainbowCFResearch@UHhospitals.org
-
Columbus, Ohio, Forente stater, 43205
- Rekruttering
- Nationwide Children's Hospital, Columbus
-
Ta kontakt med:
- Diana Gilmore
- Telefonnummer: 614-722-4752
- E-post: diana.gilmore@nationwidechildrens.org
-
Toledo, Ohio, Forente stater, 43606
- Rekruttering
- Toledo Children's Hospital
-
Ta kontakt med:
- Kelly Hoot
- Telefonnummer: 419-291-4630
- E-post: kelly.hoot@promedica.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forente stater, 17033
- Rekruttering
- Hershey Medical Center Pennsylvania State University
-
Ta kontakt med:
- Diane Kitch
- Telefonnummer: 717-531-5646
- E-post: dkitch@pennstatehealth.psu.edu
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Har ikke rekruttert ennå
- University of Pittsburgh Medical Center
-
Ta kontakt med:
- Adrienne DeRicco
- Telefonnummer: 412-692-8069
- E-post: adrienne.dericco2@upmc.edu
-
-
Texas
-
Dallas, Texas, Forente stater, 75207
- Rekruttering
- University of Texas Southwestern / Children's Health
-
Ta kontakt med:
- Keianna Brown
- Telefonnummer: 214-456-5489
- E-post: Keianna.brown@utsouthwestern.edu
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Rekruttering
- Adult Cystic Fibrosis Center at the University of Utah
-
Ta kontakt med:
- Kristyn Packer
- Telefonnummer: 801-520-5106
- E-post: kristyn.packer@hsc.utah.edu
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- Rekruttering
- University of Wisconsin
-
Ta kontakt med:
- Melanie Nelson
- Telefonnummer: 608-265-4617
- E-post: mnelson@pediatrics.wisc.edu
-
Milwaukee, Wisconsin, Forente stater, 53226
- Har ikke rekruttert ennå
- Froedtert & Medical College of Wisconsin
-
Ta kontakt med:
- Erin Hubertz
- Telefonnummer: 414-955-7019
- E-post: ehubertz@mcw.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU
-
Confirmed and documented diagnosis of CF
-
Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.
-
Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.
-
Adequate nutritional status measured by body mass index (BMI) defined by:
- BMI ≥25th percentile for children aged 12-17 years
- BMI ≥18.5 kg/m2 for ≥18 years of age
Exclusion Criteria:
- History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
- History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
- Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
- Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ANG003 Dose A
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis. |
160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Eksperimentell: ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Aktiv komparator: Creon
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis. |
The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction. |
|
Ingen inngripen: Off Enzyme
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days. |
|
|
Annen: 60% to <80% CFA ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
Tidsramme: From Visit 1 to Visit 5, anticipated average 80 days
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values |
From Visit 1 to Visit 5, anticipated average 80 days
|
|
Coefficient of Fat Absorption (CFA)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CFA collection
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
Tidsramme: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
|
Coefficient of Nitrogen Absorption (CNA)
Tidsramme: Period A (baseline) and Period B 72 hour CNA collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CNA collection
|
|
% of subjects with GI symptoms
Tidsramme: From Visit 2 to Visit 5, anticipated average 59 days
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
From Visit 2 to Visit 5, anticipated average 59 days
|
|
Cumulative stool weight
Tidsramme: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
|
Number of Stools per Day
Tidsramme: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlation between DHA/EPA and CFA
Tidsramme: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
Mean change from baseline for each treatment group with a baseline CFA ≥80% |
Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
|
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline for each treatment group with a baseline CFA 60% to <80% |
Period A (baseline) and Period B 72 hour CFA collection
|
|
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
Tidsramme: Period B 72 hour CFA collection
|
Period B CFA Off Enzyme in subjects with a baseline CFA ≥80% |
Period B 72 hour CFA collection
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Genetiske sykdommer, medfødte
- Sykdommer i luftveiene
- Sykdommer i fordøyelsessystemet
- Lungesykdommer
- Spedbarn, nyfødte, sykdommer
- Pankreassykdommer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Cystisk fibrose
- Eksokrin bukspyttkjertelinsuffisiens
- Hydrolaser
- Enzymer
- Enzymer og koenzymer
- Komplekse blandinger
- Lipase
- Karboksylesterhydrolaser
- Esteraser
- Pankreasekstrakter
- Vevekstrakter
- Pankrelipase
Andre studie-ID-numre
- ANG003-25-201
- 2025-524569-25-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .